Zheng Quan Shi Bao Wang·2025-08-24 08:25Core Insights - The report from CITIC Securities indicates that innovative nuclear medicine (RDC) is expected to address unmet clinical needs in prostate cancer diagnosis and treatment, such as high detection burdens and limited efficacy [1] - Currently, there are no RDC products available in China, presenting a blue ocean market opportunity, while overseas prostate cancer RDC products reached nearly $3 billion in market size by 2024, demonstrating significant commercial value [1] - CITIC Securities anticipates that China could replicate the development path of the overseas prostate cancer RDC market, projecting that the domestic market will exceed 10 billion yuan, indicating rapid growth [1] Industry Analysis - The key factors in this industry include radionuclides, ligand molecular forms, and production and distribution capabilities, suggesting that companies with advantages in these areas should be closely monitored [1]